Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Sorry, there are no financial reports available yet.

Investor presentations

Results: PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor

Investor Presentation Conference Call 6th July, 2020

Investor Presentation Jefferies Virtual Healthcare Conference June 3rd, 2020

JP Morgan Healthcare Conference, San Francisco, 15th January 2020

Linzagolix Phase 3 PRIMROSE 2 Trial Results

Investor Presentation 10th Annual Jefferies Global Healthcare Conference 21 November 2019

Cantor Global Healthcare Conference October 4 2019

The H.C. Wainwright 21st Annual Global Investment in NYC – September 10th 2019

1 2 3

Press Releases

ObsEva Randomizes First Patient in Phase 2b EDELWEISS Study of OBE2109 for the Treatment of Endometriosis

press release

October 12, 2016

– Clinical trial to assess safety and efficacy of novel GnRH antagonist in patients with pelvic pain associated with endometriosis…

Read more

ObsEva to Present at 2016 Wedbush Pacgrow Healthcare Conference

press release

August 10, 2016

Geneva, Switzerland, 10 August 2016 – ObsEva, a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, today announced that Ernest Loumaye,…

Read more

ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2α Antagonist, for the Treatment of Preterm Labor

press release

July 28, 2016

Geneva, Switzerland, 28 July 2016 – ObsEva, a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics from conception to…

Read more
1 78 79 80 81 82 86

General Meetings

ObsEva Annual General Meeting 2023

June 29, 2023

Read more

ObsEva Annual General Meeting 2022

May 18, 2022

Read more
1 2 3 4

Upcoming Events

Half Year 2024 Financial Results: 30 September 2024

Event


    Read more

    Annual General Meeting: Thursday 27 June, 2024

    Event


      Read more

      Obseva 2023 Swiss Annual Report: 30 April, 2024

      Event


        Read more
         

        Contacts

        ObsEva Switzerland Office

        Chemin des Aulx,12

        1228, Plan-Les-Ouates, Geneva, Switzerland

        +41 (0)22 552 3840


        contact@obseva.ch

        Investor relations


        IR@obseva.ch

        CEO Office

        +41 (0)22 552 1550


        contact@obseva.ch

         

        Sign up for news

         
         

          * Type:


          InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












          Read our privacy policy here.


           

          Are you sure you want to leave ObsEva.com?

          We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

          Continue to link

          Disclaimer

          Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

          Continue

          Disclaimer

          Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

          Continue